Pfizer Announces Neratinib Data In HER2 Positive Breast Cancer
 

Pfizer Inc. (NYSE: PFE) announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)...

More...